527 related articles for article (PubMed ID: 11362343)
1. FDA evaluates accelerated approval process. Food and Drug Administration.
Common Factor; 1995 Apr; (no 10):18. PubMed ID: 11362343
[TBL] [Abstract][Full Text] [Related]
2. Editorial: time to end the death trials.
James JS
AIDS Treat News; 1996 Aug; (no 252):1-4. PubMed ID: 11363751
[TBL] [Abstract][Full Text] [Related]
3. FDA looks at full approval for d4T. Food and Drug Administration.
Posit Aware; 1996; 7(1):7. PubMed ID: 11363131
[TBL] [Abstract][Full Text] [Related]
4. AIDS task force grapples with faster access to protease drugs.
Mascolini M
J Int Assoc Physicians AIDS Care; 1995 Mar; 1(2):6-11. PubMed ID: 11362314
[TBL] [Abstract][Full Text] [Related]
5. Potent new AIDS drugs underscore promise of combination therapy.
AIDS Alert; 1996 Jan; 11(1):1-4. PubMed ID: 11363225
[TBL] [Abstract][Full Text] [Related]
6. FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
Mascolini M
AIDS Treat News; 1996 Dec; (No 260):3-5. PubMed ID: 11364022
[TBL] [Abstract][Full Text] [Related]
7. Protease inhibitor consensus statement.
AIDS Treat News; 1995 Mar; (no 219):7. PubMed ID: 11362333
[TBL] [Abstract][Full Text] [Related]
8. AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.
James JS
AIDS Treat News; 1996 Apr; (no 244):6. PubMed ID: 11363307
[TBL] [Abstract][Full Text] [Related]
9. Saquinavir gets accelerated approval.
McGuire S
Posit Aware; 1996; 7(1):8. PubMed ID: 11363135
[TBL] [Abstract][Full Text] [Related]
10. FDA community meeting May 16: clinical trials and viral load. Food and Drug Administration.
AIDS Treat News; 1997 May; (No 270):3. PubMed ID: 11364324
[TBL] [Abstract][Full Text] [Related]
11. FDA approves first new class of HIV drugs. Food and Drug Administration.
AIDS Alert; 1996 Aug; 11(8):89. PubMed ID: 11363655
[TBL] [Abstract][Full Text] [Related]
12. Delavirdine dilemma at the FDA. Food and Drug Administration.
Smart T
GMHC Treat Issues; 1996 Dec; 10(12):4-5. PubMed ID: 11364017
[TBL] [Abstract][Full Text] [Related]
13. FDA workshop on clinical trial design, September 6-7--registration by Aug. 18. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Aug; (no 228):5-6. PubMed ID: 11362627
[TBL] [Abstract][Full Text] [Related]
14. Three days that shook the world.
Gilden D; Smart T
GMHC Treat Issues; 1996 Mar; 10(3):1-5. PubMed ID: 11363388
[TBL] [Abstract][Full Text] [Related]
15. Protease inhibitor update: treatment combination strategies.
Mascolini M
AIDS Treat News; 1996 Jan; (no 239):3. PubMed ID: 11363085
[TBL] [Abstract][Full Text] [Related]
16. FDA reform in Congress: AIDS community absent. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Apr; (no 220):4-5. PubMed ID: 11362320
[TBL] [Abstract][Full Text] [Related]
17. FDA triple header. Food and Drug Administration.
Smart T
GMHC Treat Issues; 1995 Nov; 9(11):1-3. PubMed ID: 11362986
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine (3TC) approved for combination use with AZT.
James JS
AIDS Treat News; 1995 Dec; (no 236):1-5. PubMed ID: 11363049
[TBL] [Abstract][Full Text] [Related]
19. FDA antiviral advisory hearings on lamivudine (Epivir, 3TC), saquinavir (Invirase), stavudine (Zerit, d4T), November 6-8. Food and Drug Administration.
AIDS Treat News; 1995 Oct; (no 233):4-5. PubMed ID: 11363038
[TBL] [Abstract][Full Text] [Related]
20. Let there be drugs.
Gilden D
GMHC Treat Issues; 1996 Feb; 10(2):1, 13-6. PubMed ID: 11363380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
